A
Arnon Nagler
Researcher at Sheba Medical Center
Publications - 1435
Citations - 51740
Arnon Nagler is an academic researcher from Sheba Medical Center. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 98, co-authored 1316 publications receiving 44298 citations. Previous affiliations of Arnon Nagler include French Institute of Health and Medical Research & University of Paris.
Papers
More filters
Journal ArticleDOI
Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the acute leukemia working party of the EBMT
Johanna Waidhauser,Myriam Labopin,Jordi Esteve,Nicolaus Kröger,Jan J. Cornelissen,Tobias Gedde-Dahl,Gwendolyn Van Gorkom,Jürgen Finke,Montserrat Rovira,Nicolaas Schaap,Eefke Petersen,Dietrich W. Beelen,Donald Bunjes,Bipin N. Savani,Christoph Schmid,Arnon Nagler,Mohamad Mohty +16 more
Abstract: Acute myeloid leukemia with runt-related transcription factor 1 gene mutation (RUNX1+ AML) is associated with inferior response rates and outcome after conventional chemotherapy. We performed a retrospective, registry-based analysis to elucidate the prognostic value of RUNX1 mutation after allogeneic stem cell transplantation (alloSCT). All consecutive adults undergoing alloSCT for AML in first complete remission (CR1) between 2013 and 2019 with complete information on conventional cytogenetics and RUNX1 mutational status were included. Endpoints of interest were cumulative relapse incidence, non-relapse mortality, overall and leukemia-free survival (OS/LFS), and GvHD-free/relapse-free survival. A total of 674 patients (183 RUNX1+, 491 RUNX1−) were identified, with >85% presenting as de novo AML. Median follow-up was 16.4 (RUNX1+) and 21.9 (RUNX1−) months. Survival rates showed no difference between RUNX1+ and RUNX1− patients either in univariate or multivariate analysis (2-year OS: 67.7 vs. 66.1%, p = 0.7; 2-year LFS: 61.1 vs. 60.8%, p = 0.62). Multivariate analysis identified age, donor type and poor cytogenetics as risk factors for inferior outcome. Among patients with RUNX+ AML, older age, reduced intensity conditioning and minimal residual disease at alloSCT predicted inferior outcome. Our data provide evidence that the negative influence of RUNX1 mutations in patients with AML can be overcome by transplantation in CR1.
Journal ArticleDOI
Sensitive Replicate Real-Time Quantitative PCR of BCR-ABL Shows Deep Molecular Responses in Long-Term Post-Allogeneic Stem Cell Transplantation Chronic Myeloid Leukemia Patients.
Maya Koren-Michowitz,Maya Koren-Michowitz,Avichai Shimoni,Filomena Daraio,Francesca Crasto,Roberta Lorenzatti,Yulia Volchek,Ninette Amariglio,Enrico Gottardi,Giuseppe Saglio,Arnon Nagler,Arnon Nagler +11 more
TL;DR: Cure from CML in the majority of allogeneic SCT patients who have no transcripts detectable by replicate RT-qPCR for BCR-ABL is suggested.
Journal ArticleDOI
Impact of the addition of antithymocyte globulin to post-transplant cyclophosphamide in haploidentical transplantation with peripheral blood compared to post-transplant cyclophosphamide alone in acute myeloid leukemia: a retrospective study on behalf of the Acute Leukemia Working Party of the EBMT.
Giorgia Battipaglia,Myriam Labopin,Didier Blaise,José Luis Díez-Martín,Ali Bazarbachi,Antonin Vitek,Patrice Chevallier,Luca Castagna,Giovanni Grillo,Etienne Daguindau,Javier López-Jiménez,Yener Koc,Annalisa Ruggeri,Arnon Nagler,Mohamad Mohty +14 more
TL;DR: The use of haplo-identical hematopoietic cell transplantation (haplo-HCT) with peripheral blood stem cells (PBSCs) to treat acute myelogenous leukemia (AML) is increasing as mentioned in this paper .
Journal ArticleDOI
Progression of disease within 24 months of initial therapy (POD24) detected incidentally in imaging does not necessarily indicate worse outcome
Guy Bitansky,Abraham Avigdor,Abraham Avigdor,Elena Vasilev,Maya Zlotnick,Elena Ribakovsky,Ohad Benjamini,Ohad Benjamini,Arnon Nagler,Arnon Nagler,Meirav Kedmi,Meirav Kedmi,Meirav Kedmi +12 more
TL;DR: Progression of disease within 24 months of initial therapy (POD24) has previously been identified as a predictor of reduced overall survival (OS) for patients with follicular lymphoma (FL) and this finding is validated.
Journal ArticleDOI
COVID-19 in Hematologic Malignancies: Big Challenges.
TL;DR: This poster presents a poster presented at the 2016 China Hematology and Bone Marrow Transplantation Conference, presenting the results of a £1.3m study to characterize the immune response to bone marrow transplantation.